While the SARS-CoV-2 pandemic is heavily hitting the world, it is of extreme importance that significant in vitro observations guide the quick set up of clinical trials. In this study, we evidence that the anti-SARS-CoV2 activity of a clinically achievable hydroxychloroquine concentration is maximized only when administered before and after the infection of Vero E6 and Caco-2 cells. This suggests that only a combined prophylactic and therapeutic use of hydroxychloroquine may be effective in limiting viral replication in patients.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, therapy, Hydroxychloroquine, Prophylaxis, 【초록키워드】 pandemic, Infection, clinical trials, in vitro, Prophylactic, viral replication, patients, Caco-2 cells, Evidence, Concentration, Vero E6, observation, therapeutic use, while, Administered, effective, extreme, clinically, the SARS-CoV-2, 【제목키워드】 in vitro, Effect, Combined,
【저자키워드】 COVID-19, SARS-CoV-2, therapy, Hydroxychloroquine, Prophylaxis, 【초록키워드】 pandemic, Infection, clinical trials, in vitro, Prophylactic, viral replication, patients, Caco-2 cells, Evidence, Concentration, Vero E6, observation, therapeutic use, while, Administered, effective, extreme, clinically, the SARS-CoV-2, 【제목키워드】 in vitro, Effect, Combined,